SPICLOMAZINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H24ClN3OS2
Molecular Weight	446.028
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=CC2=C(SC3=CC=CC=C3N2CCCN4CCC5(CC4)NC(=O)CS5)C=C1

InChI

InChIKey=CFOYBMUYCBSDAL-UHFFFAOYSA-N

InChI=1S/C22H24ClN3OS2/c23-16-6-7-20-18(14-16)26(17-4-1-2-5-19(17)29-20)11-3-10-25-12-8-22(9-13-25)24-21(27)15-28-22/h1-2,4-7,14H,3,8-13,15H2,(H,24,27)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6111088 | https://www.ncbi.nlm.nih.gov/pubmed/23840452 | https://www.ncbi.nlm.nih.gov/pubmed/16772768https://www.ncbi.nlm.nih.gov/pubmed/23840452

Spiclomazine induces apoptosis associated with the suppression of migration and invasion in pancreatic carcinoma cells

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
apoptotic process 48 Target ID: GO:0006915 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23840452	Activator 1430
transformed cell apoptotic process 108 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23840452	Activator 1430
Adrenergic receptor 35 Target ID: CHEMBL2331074 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6111088	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Psychotic disorder 26 Sources: https://www.ncbi.nlm.nih.gov/pubmed/5465392 https://www.ncbi.nlm.nih.gov/pubmed/6111088 https://www.ncbi.nlm.nih.gov/pubmed/5465391	Primary		Approved 8429	Diceplon Approved Use Antipsychotic
Pancreatic cancer 97 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23840452	Primary		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses.	1981 Feb	6111088

Patents

Sample Use Guides

In Vivo Use Guide

oral administration of 5-10 mg

Route of Administration: Oral

In Vitro Use Guide

Treatment with Clospirazine hydrochloride (spiclomazine) for 24 and 48 h resulted in a time and dose-dependent growth reduction of CFPAC-1 and MIA PaCa-2 cell lines examined by MTT assay. This small molecule inhibited the cell growth to approximately 61.1+/-5.3%, 76.4+/-3.2% and 90.4+/-0.5% of control in CFPAC-1 cells, and 79.3+/-1.0%, 84.5+/-1.5% and 93.6+/-0.2% of control in MIA PaCa-2 cells at the concentrations of 30, 40, and 50 mg/mL for 48 h, respectively.

Name

Type

Language

SPICLOMAZINE

Official Name

English

Spiclomazine [WHO-DD]

Common Name

English

CLOSPIRAZINE [MI]

Common Name

English

spiclomazine [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29710